Announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ ...
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024Toronto, Ontario--(Newsfile Corp. - September...
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...
Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study ...
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients...
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis ARCHER...
Monday U.S. Featured Earnings Legend Biotech Corporation (NASDAQ: LEGN) (Q1) EPS ...
Cardiol Therapeutics (CRDL), a clinical-stage life sciences company, is researching and developing new drugs to fight inflammation and scarring in the heart. Their main drug, CardiolRx™, is b
Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in patients withrecurrent pericarditis, with topline results expected in Q2 2024CardiolRx™ granted U.S. FDA Orphan...